Cleveland Clinic Published Its Selection of Top Three “Groundbreaking” Pharmaceutics

As usual, Cleveland Clinic will pick out some “groundbreaking” pharmaceutics that may make big difference for healthcare industry in their late development stages. This year who will be picked by Cleveland? According to internal news, Gilead's sofosbuvir, Novartis’ heart drugs serelaxin as well as Pharmacyclics and J&J' cancer drug ibrutinib are the top three.

Sofosbuvir is used to treat hepatitis C, be administered orally. Sofosbuvir is considered to be able to replace the currently used injectable interferon treatment.

Serelaxin is a synthetic hormone even can be used for pregnant women without significant side effects and experts believe that the new drug might shock cardiovascular field.

Ibrutinib is mediated through the activation of B cells of the immune system to inhibit proliferation of cancer cells.

All of the three drugs have aimed to ear FDA’s “breakthrough therapy”.

This year's ranking also highlights the contribution of smaller biotechs, for example, many of the top list gains of large-scale pharmaceutical companies actually come from acquiring of small pharmaceutical companies’.

Article Link: Cleveland Clinic Published Its Selection of Top Three “Groundbreaking” Pharmaceutics